Schrodinger Inc. (NASDAQ: SDGR) reported Q1 EPS of ($0.86), $0.10 worse than the analyst estimate of ($0.76). Revenue for the quarter came in at $36.6 million versus the consensus estimate of $41.96 million.

2024 Financial Outlook
As of May 1, 2024, Schrödinger maintained its financial guidance for the fiscal year ending December 31, 2024:

Software revenue growth is expected to range from 6% to 13%.
Drug discovery revenue is expected to range from $30 million to $35 million.
Software gross margin is expected to be similar to software gross margin for the full year 2023.
Operating expense growth in 2024 is expected to range from 8% to 12%.
Cash used for operating activities in 2024 is expected to be above cash used for operating activities in 2023.

For the second quarter of 2024, software revenue is expected to range from $31 million to $33 million.

For earnings history and earnings-related data on Schrodinger Inc. (SDGR) click here.